Skip to main content
logo
Latigo Biotherapeutics, Inc. (LTGO)
NASDAQ: LTGO · Real-Time Price · USD
21.77
-0.49 (-2.20%)
Sep 2, 2026, 4:00 PM EDT - Market closed

Latigo Biotherapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Mar '26 Dec '25 Dec '24
Net Income
-111.18-109.17-61.18
Depreciation & Amortization
0.230.250.24
Stock-Based Compensation
7.236.732.77
Other Operating Activities
2.212.120.33
Change in Accounts Payable
-2.5-1.965.75
Change in Other Net Operating Assets
0.544.481.14
Operating Cash Flow
-103.47-97.56-50.96
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Mar '26 Dec '25 Dec '24
Capital Expenditures
-0.03-0.14-0.07
Investing Cash Flow
-0.03-0.14-0.07

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Mar '26 Dec '25 Dec '24
Issuance of Common Stock
0.20.120.61
Financing Cash Flow
49.83149.50.61

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Mar '26 Dec '25 Dec '24
Net Cash Flow
-53.6751.8-50.42

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Mar '26 Dec '25 Dec '24
Free Cash Flow
-103.5-97.69-51.03
Free Cash Flow Growth
---
Free Cash Flow Per Share
-18.38-18.00-11.70
Levered Free Cash Flow
--59.47-
Unlevered Free Cash Flow
--59.47-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Mar '26 Dec '25 Dec '24
Change in Working Capital
-1.962.526.89
SEC Filings: 10-K · 10-Q